Prognostic value of survivin in patients with non-small cell lung carcinoma: A systematic review with meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhang, Lou Qian ^a   Wang, Jun ^b   Jiang, Feng ^a   Xu, Lin ^a   Liu, Fu Yin ^b   Yin, Rong ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b Jiangsu Province Official Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

CANCER STAGING; CANCER SURGERY; ETHNICITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RACE; REVIEW; SYSTEMATIC REVIEW; BLOOD; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; PROGNOSIS;

EID: 84863365307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034100     Document Type: Review

References (56)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594.
3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, et al. (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796.
4. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, et al. (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221-1230.
5. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, et al. (2007) The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 13: 73-77.
6. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG, (2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44: 946-953.
7. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320.
8. Samuel T, Okada K, Hyer M, Welsh K, Zapata JM, et al. (2005) cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 65: 210-218.
9. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, et al. (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99: 4349-4354.
10. Sah NK, Khan Z, Khan GJ, Bisen PS, (2006) Structural, functional and therapeutic biology of survivin. Cancer Letters 244: 164-171.
11. Ryan BM, O'Donovan N, Duffy MJ, (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562.
12. Kim GY, Lim SJ, Kim YW, (2011) Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas. Modern Pathology.
13. Zhang Q, Zhang ZF, Yue DS, Wang CL, (2010) Expression of CD44v6, survivin, β-Catenin in Bronchioloalveolar Carcinoma and Their Prognostic Implications. Chinese Cancer Research on Prevention and Treatment 37: 909-912.
14. Zhang JR, Mei YY, Liu LK, (2010) Correlation of PTEN,PI3K and survivin expression in non-small cell lung cancer. Chinese Clinical Oncology 15: 789-793.
15. Yang DX, Li NE, Ma Y, Han YC, Shi Y, (2010) Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density. Chin J Cancer 29: 396-402.
16. Weng XW, Zhang JH, Ren Z, Liang CZ, Lin PF, (2010) Expression of survivin and correlation between it and prognosis of NSCLC. Chinese Journal of Cancer Prevention and Treatment 17: 198-200.
17. Porebska I, Sobanska E, Kosacka M, Jankowska R, (2010) Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer. Cancer Genomics Proteomics 7: 331-335.
18. Nakashima N, Huang CL, Liu D, Ueno M, Yokomise H, (2010) Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer. Int J Oncol 37: 687-694.
19. Lv XY, Li QS, Liu CY, (2010) The relationship between expression of survivin and its biological characteristic,prognosis in non-small cell lung cancer. Journal of Clinical Pulmonary Medicine 15: 5-6.
20. Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, et al. (2010) Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol 5: 1354-1360.
21. Dai CH, Li J, Shi SB, Yu LC, Ge LP, et al. (2010) Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 40: 327-335.
22. Chen P, Li J, Ge LP, Dai CH, Li XQ, (2010) Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 15: 501-509.
23. Yie Sm, Lou B, Ye Sr, He X, Cao M, et al. (2009) Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 63: 284-290.
24. Yamashita S, Chujo M, Miyawaki M, Tokuishi K, Anami K, et al. (2009) Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J Exp Clin Cancer Res 28: 22.
25. Mohamed S, Yasufuku K, Nakajima T, Hiroshima K, Chiyo M, et al. (2009) Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications. Eur Respir J 33: 127-133.
26. Hoshil F, Endo C, Sakurada A, Matsumura Y, Okada Y, et al. (2009) Immunohistochemical study of an anti-apoptotic protein survivin in lung cancer. Japanese Journal of Lung Cancer 49: 12-16.
27. Chen X, Luo S, Li N, Song Y, Zen J, (2009) Relationship between the expression of ERCC-1, survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma. Chinese-German Journal of Clinical Oncology 8: 265-268.
28. Li C, Hu B, Wang X, Ji C, He Y, (2008) Expression and clinical significance of caspase-3,survivin and k-ras in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 11: 90-96.
29. Bria E, Visca P, Novelli F, Casini B, Diodoro MG, et al. (2008) Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol 34: 593-598.
30. Zhu ZH, Yang H, Fu JH, Hu Y, Ma Y, et al. (2007) Expression and prognostic value of survivin protein in early-stage non-small cell lung cancer. Ai Zheng 26: 1268-1271.
31. Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, et al. (2007) Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 22: 318-325.
32. Wang DF, Zeng CG, Lin YB, Hou JH, Zhu ZH, (2006) Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer. Ai Zheng 25: 359-362.
33. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G, (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5: 2905-2913.
34. Atikcan S, Unsal E, Demirag F, Koksal D, Yilmaz A, (2006) Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med 100: 2220-2226.
35. Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C, (2006) Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 449: 164-170.
36. Zhou JM, Zhou JH, Deng ZH, Zheng H, Jiang HY, et al. (2005) Expression of survivin and proliferating cell nuclear antigen in human non-small cell lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30: 544-548.
37. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, et al. (2005) Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103: 1685-1692.
38. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Pilecka I, et al. (2005) Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 43: 237-242.
39. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, et al. (2004) Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 12: 44-49.
40. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, et al. (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626.
41. Ikehara M, Oshita F, Kameda Y, Ito H, Ohgane N, et al. (2002) Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 9: 835-838.
42. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, et al. (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104.
43. Jamieson NB, Carter CR, McKay CJ, Oien KA, (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17: 3316-3331.
44. Li F, Yang J, Ramnath N, Javle MM, Tan D, (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114: 509-512.
45. Fan J, Wang L, Jiang GN, He WX, Ding JA, (2008) The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 61: 91-96.
46. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
47. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A, (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364: 947-955.
48. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, et al. (1994) p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69: 846-852.
49. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2: 416-422.
50. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719.
51. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
52. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
53. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
54. Thompson SG, Higgins JP, (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21: 1559-1573.
55. Tobias A, (1999) Assessing the influence of a single study in the meta-anyalysis estimate. Stata Technical Bulletin 8: 15-27.
56. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629-634.